STAT

Empty desks, squabbles, inexperienced staff: Exactly who is coordinating White House drug policy?

A year and a half into the Trump administration, it remains unclear who, besides Kellyanne Conway, is coordinating U.S. drug policy in the midst of an opioid crisis.
(From left) FDA Commissioner Scott Gottlieb, former New Jersey Governor Chris Christie, acting ONDCP Director Jim Carroll, HHS Secretary Alex Azar, and White House aide Kellyanne Conway

WASHINGTON — For at least six months, staffers in the Office of National Drug Control Policy — often political appointees in their 20s — have crossed 17th Street, entered the Eisenhower Executive Office Building, and sat through weekly meetings of an “opioids cabinet” chaired by Kellyanne Conway.

Then they have returned to their desks and reported back to veteran career staff — who have listened, often with disappointment, to the ideas proposed by Conway and Katy Talento, a domestic policy adviser.

The pair insisted at one point that an opioid awareness campaign focus on fentanyl, a concept opposed by those with experience in substance use prevention. Separately, Conway outlined a plan for a marketing partnership with the NFL and MLB, an idea that has not yet materialized.

Frustrations with the meetings, according to officials familiar with them, are symptomatic of a broader issue: A

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks